Press Releases

Press Releases
Date Title and Summary View
Jun 19, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jonathan Biller as Executive Vice President and General Counsel effective July 3, 2018. Mr. Biller will be responsible for global legal strategy and will serve on the company's Executive Committee. ...
Jun 3, 2018 Updated results with liso-cel underscore potential for best-in-class CAR T profile for patients with poor prognosis SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced updated six-month safety and efficacy data from the TRANSCEND (NHL-001) study of liso...
Jun 3, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented at the 54th Annual Amer...
Jun 1, 2018 High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated patients in the active doses of the dose escalation cohort Consistent response observed for both low and high BCMA expre...
Jun 1, 2018 The OPTIMISMM study is the first Phase 3 Study to report findings for a triplet combination regimen in which 100% of patients have received prior lenalidomide therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, ...
May 31, 2018 David Elkins most recently served as Worldwide Vice President and CFO for Consumer Products, Medical Devices and Corporate Functions at Johnson & Johnson Peter Kellogg to remain on Executive Committee as EVP, Chief Corporate Strategy Officer until his retirement, planned for mid-2019 ...
May 24, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock. In addition, the Company plans to enter into an accelerated share repurchase (ASR) agreement to repurchase a...
May 22, 2018 Presentations highlight Celgene's ongoing innovative research, including the use of CAR T cell therapies to treat multiple myeloma and lymphoma, and therapies for the treatment of multiple blood disorders, including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia ...
May 16, 2018 Presentations highlight the value of innovative research in key disease areas including multiple myeloma, lymphoma, acute myeloid leukemia and squamous non-small cell lung cancer, as well as novel CAR T technology SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) to...
May 14, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company. The events will be webcast live and will be available in the Investor Relations section of the Company's website at...
1
... NextLast
Add to Briefcase = add release to Briefcase